[1]
Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010; 7(2): 103-9.
[2]
Oresland T, Bemelman WA, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn’s Colitis 2015; 9(1): 4-25.
[3]
Brown SR, Faiz OD. Ileoanal pouch report Association of coloproctology of Ireland and Great Britain. 2017.
[4]
Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103(5): 1444-51.
[5]
Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ecco. J Crohn’s Colitis 2016; 10(2): 216-25.
[6]
Niewiadomski O, Studd C, Hair C, et al. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity. J Gastroenterol Hepatol 2015; 30(9): 1346-53.
[7]
Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19(9): 2001-10.
[8]
de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010; 7(2): 93-101.
[9]
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462-76.
[10]
Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57(4): 549-58.
[11]
Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134(4): 929-36.
[12]
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098-104.
[13]
Melville DM, Ritchie JK, Nicholls RJ, Hawley PR. Surgery for ulcerative colitis in the era of the pouch: the St Mark’s Hospital experience. Gut 1994; 35(8): 1076-80.
[14]
Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222(2): 120-7.
[15]
Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987; 139(10): 3406-15.
[16]
Mooney DP, O’Reilly M, Gamelli RL. Tumor necrosis factor and wound healing. Ann Surg 1990; 211(2): 124-9.
[17]
Fu X, Tian H, Hsu S, Wang D, Sheng Z. In vivo effects of tumor necrosis factor-alpha on incised wound and gunshot wound healing. J Trauma 1996; 40(3)(Suppl.): S140-3.
[18]
Salomon GD, Kasid A, Cromack DT, et al. The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg 1991; 214(2): 175-80.
[19]
Rapala K, Laato M, Niinikoski J, et al. Tumor necrosis factor alpha inhibits wound healing in the rat. Eur Surg Res 1991; 23(5-6): 261-8.
[20]
Baek SJ, Dozois EJ, Mathis KL, et al. Safety, feasibility, and short-term outcomes in 588 patients undergoing minimally invasive ileal pouch-anal anastomosis: a single-institution experience. Tech Coloproctol 2016; 20(6): 369-74.
[21]
Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol 2018; 32-33: 71-8.
[22]
de Buck van Overstraeten A, Wolthuis AM, D’Hoore A. Transanal completion proctectomy after total colectomy and ileal pouch-anal anastomosis for ulcerative colitis: a modified single stapled technique. Colorectal Dis 2016; 18(4): O141-4.
[23]
McKenna NP, Dozois EJ, Pemberton JH, Lightner AL. Impact of sex on 30-day complications and long-term functional outcomes following ileal pouch-anal anastomosis for chronic ulcerative colitis. Int J Colorectal Dis 2018; 33(5): 619-25.
[24]
Mark-Christensen A, Erichsen R, Brandsborg S, et al. Pouch failures following ileal pouch-anal anastomosis for ulcerative colitis. Colorectal Dis 2018; 20(1): 44-52.
[25]
Kiely JM, Fazio VW, Remzi FH, Shen B, Kiran RP. Pelvic sepsis after IPAA adversely affects function of the pouch and quality of life. Dis Colon Rectum 2012; 55(4): 387-92.
[26]
Sagap I, Remzi FH, Hammel JP, Fazio VW. Factors associated with failure in managing pelvic sepsis after ileal pouch-anal anastomosis (IPAA)--a multivariate analysis. Surgery 2006; 140(4): 691-703.
[27]
Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-tumor necrosis factor-alpha antibody therapy management before and after intestinal surgery for inflammatory bowel disease: A CCFA Position Paper. Inflamm Bowel Dis 2015; 21(11): 2658-72.
[28]
Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204(5): 956-62.
[29]
Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51(8): 1202-7.
[30]
Eshuis EJ, Al Saady RL, Stokkers PC, et al. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohn’s Colitis 2013; 7(2): 142-9.
[31]
Krane MK, Allaix ME, Zoccali M, et al. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. Dis Colon Rectum 2013; 56(4): 449-57.
[32]
Norgard BM, Nielsen J, Qvist N, et al. Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with ulcerative colitis-a nationwide cohort study. Aliment Pharmacol Ther 2012; 35(11): 1301-9.
[33]
Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 50(11): 1747-53.
[34]
Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12(10): 1730-6.
[35]
Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15(7): 1062-70.
[36]
Zittan E, Milgrom R, Ma GW, et al. Preoperative anti-tumor necrosis factor therapy in patients with ulcerative colitis is not associated with an increased risk of infectious and noninfectious complications after ileal pouch-anal anastomosis. Inflamm Bowel Dis 2016; 22(10): 2442-7.
[37]
Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010; 31(4): 486-92.
[38]
Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36(10): 922-8.
[39]
Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis 2015; 21(1): 79-92.
[40]
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5(2): 119-33.
[41]
Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46(8): 645-60.
[42]
Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30(4): 523-9.
[43]
Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015; 261(3): 487-96.
[44]
Waterman M, Xu W, Dinani A, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013; 62(3): 387-94.
[45]
Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10(10): 1079-87.
[46]
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis 2017; 11(6): 649-70.
[47]
von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61(4): 344-9.
[48]
Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-alpha therapy. Dis Colon Rectum 2013; 56(11): 1243-52.
[49]
Gu J, Stocchi L, Ashburn J, Remzi FH. Total abdominal colectomy vs. restorative total proctocolectomy as the initial approach to medically refractory ulcerative colitis. Int J Colorectal Dis 2017; 32(8): 1215-22.
[50]
Bikhchandani J, Polites SF, Wagie AE, Habermann EB, Cima RR. National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. Dis Colon Rectum 2015; 58(2): 199-204.
[51]
Geltzeiler CB, Lu KC, Diggs BS, et al. Initial surgical management of ulcerative colitis in the biologic era. Dis Colon Rectum 2014; 57(12): 1358-63.
[52]
Kulaylat AS, Kulaylat AN, Schaefer EW, et al. Association of Preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis. JAMA Surg 2017; 152(8): e171538.
[53]
Coquet-Reinier B, Berdah SV, Grimaud JC, et al. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc 2010; 24(8): 1866-71.
[54]
Gainsbury ML, Chu DI, Howard LA, et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg 2011; 15(3): 397-403.
[55]
Carlsson E, Fingren J, Hallen AM, Petersen C, Lindholm E. The prevalence of ostomy-related complications 1 year after ostomy surgery: A prospective, descriptive, clinical study. Ostomy Wound Manage 2016; 62(10): 34-48.
[56]
Swenson BR, Hollenbeak CS, Poritz LS, Koltun WA. Modified two-stage ileal pouch-anal anastomosis: equivalent outcomes with less resource utilization. Dis Colon Rectum 2005; 48(2): 256-61.
[57]
Zittan E, Wong-Chong N, Ma GW, et al. Modified Two-stage ileal pouch-anal anastomosis results in lower rate of anastomotic leak compared with traditional two-stage surgery for ulcerative colitis. J Crohn’s Colitis 2016; 10(7): 766-72.
[58]
Sahami S, Buskens CJ, Fadok TY, et al. Defunctioning Ileostomy is not associated with reduced leakage in proctocolectomy and ileal pouch anastomosis surgeries for IBD. J Crohn’s Colitis 2016; 10(7): 779-85.
102
3
